Zevra Therapeutics Files 8-K

Ticker: ZVRA · Form: 8-K · Filed: Mar 5, 2024 · CIK: 1434647

Zevra Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyZevra Therapeutics, Inc. (ZVRA)
Form Type8-K
Filed DateMar 5, 2024
Risk Levellow
Pages2
Reading Time2 min
Sentimentneutral

Sentiment: neutral

Topics: 8-K, disclosure, filing

Related Tickers: ZEVRA

TL;DR

Zevra filed an 8-K, standard disclosure stuff, no major news.

AI Summary

Zevra Therapeutics, Inc. filed an 8-K on March 5, 2024, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific financial figures or material events beyond the standard reporting requirements.

Why It Matters

This 8-K filing serves as a routine update for investors, indicating the company has submitted required disclosures and financial information to the SEC.

Risk Assessment

Risk Level: low — The filing is a routine disclosure and does not appear to contain any new material information that would immediately impact the company's risk profile.

Key Players & Entities

  • ZEVRA THERAPEUTICS, INC. (company) — Registrant
  • 0001434647 (company) — Central Index Key
  • 20240305 (date) — Filing Date
  • March 5, 2024 (date) — Date of Earliest Event Reported
  • 1180 Celebration Boulevard, Suite 103, Celebration, FL 34747 (location) — Principal Executive Offices

FAQ

What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to report a Regulation FD Disclosure and to provide Financial Statements and Exhibits.

What is the exact name of the registrant filing this report?

The exact name of the registrant is Zevra Therapeutics, Inc.

On what date was this report filed?

This report was filed on March 5, 2024.

What is the company's principal executive office address?

The company's principal executive office is located at 1180 Celebration Boulevard, Suite 103, Celebration, FL 34747.

Does this filing indicate any specific new material events or financial results?

No, this filing primarily serves as a routine disclosure and does not specify any new material events or detailed financial results within the provided text.

Filing Stats: 526 words · 2 min read · ~2 pages · Grade level 10.3 · Accepted 2024-03-05 07:34:45

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. Investor Presentation On March 5, 2024, Zevra Therapeutics, Inc. released a presentation that it intends to use from time to time in meetings with investors. A copy of the presentation is attached hereto as Exhibit 99.1. The information set forth in this item 7.01 and in the attached Exhibit 99.1 is being "furnished" and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of Section 18, nor shall it be deemed incorporated by reference into any filing of the company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in any such filing.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 March 2024 Investor Presentation 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Zevra Therapeutics, Inc . Date: March 5, 2024 By: /s/ Timothy J. Sangiovanni Timothy J. Sangiovanni, CPA Senior Vice President, Corporate Controller

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.